FDA asks Lilly for more data
The U.S. Food and Drug Administration has requested additional post‑marketing studies and safety data from Eli Lilly related to its newly approved oral weight‑loss pill, citing concerns about possible heart and liver risks. The regulator's request focuses on cardiovascular and hepatic monitoring in real‑world use and requires Lilly to provide further evidence after approval. Lilly has also filed for approvals in over 40 countries and is expanding manufacturing capacity for international launches. (reuters.com)
The Food and Drug Administration approved Eli Lilly’s new obesity pill on April 1, then told the company to run more studies on possible heart and liver risks. (fda.gov) The drug is Foundayo, Lilly’s brand name for orforglipron, a once-daily pill for adults with obesity or overweight with weight-related medical problems. Lilly said prescriptions were accepted immediately after approval, with shipping starting April 6. (investor.lilly.com) In its approval letter, the agency required postmarketing trials to assess risks of liver injury, cardiovascular events and delayed stomach emptying, and also ordered a lactation study measuring drug levels in breast milk. Reuters reported the letter was signed April 1 and posted later on the Food and Drug Administration website. (fda.gov) (reuters.com) That is how drug oversight often works after approval: the Food and Drug Administration can require follow-up studies when it wants clearer answers about risks that may show up in broader real-world use. The agency’s public database says these postmarketing requirements are tracked after approval and can include studies ordered under federal law. (fda.gov 1) (fda.gov 2) Foundayo matters because it is an obesity treatment in pill form, not an injection, in a market dominated by weekly shots. The Food and Drug Administration said the approval came 50 days after filing under the Commissioner’s National Priority Voucher pilot program and 294 days before the original January 20, 2027 target date. (fda.gov) The medicine works by mimicking glucagon-like peptide-1, a gut hormone that helps control appetite and blood sugar. Lilly said Foundayo is the only approved glucagon-like peptide-1 pill for weight loss that can be taken without food or water restrictions. (investor.lilly.com) Clinical trial results cited in coverage of the approval showed substantial weight loss over 72 weeks, helping explain why Lilly has pushed the product quickly into the market. The American Journal of Managed Care reported placebo-adjusted weight reduction of roughly 9 to 11 percentage points in the ATTAIN program. (ajmc.com) Lilly has told investors it has filed for approval in more than 40 countries and is expanding manufacturing for international launches. The extra studies mean the rollout will continue alongside new safety reporting, not instead of it. (reuters.com)
